サンプル依頼リスト カート
  • English
  • Korean
市場調査レポート
商品コード
1319147

アトピー性皮膚炎の世界市場-2023年～2030年

Global Atopic Dermatitis Market - 2023-2030
出版日: | 発行: DataM Intelligence | ページ情報: 英文 195 Pages | 納期: 約2営業日

● お客様のご希望に応じて、既存データの加工や未掲載情報（例：国別セグメント）の追加などの対応が可能です。　 詳細はお問い合わせください。
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=155.85円
アトピー性皮膚炎の世界市場-2023年～2030年
出版日: 2023年07月31日
発行: DataM Intelligence
ページ情報: 英文 195 Pages
納期: 約2営業日
ご注意事項 :
本レポートは最新情報反映のため適宜更新し、内容構成変更を行う場合があります。ご検討の際はお問い合わせください。
  • 全表示
  • 概要
  • 目次
概要

市場概要

世界のアトピー性皮膚炎市場は2022年に58億米ドルに達し、2030年には165億米ドルに達する見通しで、有利な成長が予測されています。世界のアトピー性皮膚炎市場は、予測期間中（2023-2030年）に14.4%のCAGRを示すと予測されています。アトピー性皮膚炎に対する新たな治療アプローチを模索し、革新的な医薬品を特定するための研究開発活動が活発化していることが、アトピー性皮膚炎市場動向の需要を押し上げています。

アトピー性皮膚炎市場は世界的に大きな成長を遂げています。世界のアトピー性皮膚炎市場では、生物学的製剤、標的局所治療薬、個別化医療アプローチなどの革新的治療法の開発が活発化しています。モノクローナル抗体などの生物学的製剤は、アトピー性皮膚炎に関与する特定の免疫経路を標的とすることで、臨床試験で良好な結果を示しています。さらに、ドラッグデリバリーシステムの進歩や新しい外用剤の導入は、利便性、有効性、患者のコンプライアンスを向上させることを目的としています。

アトピー性皮膚炎市場は、アトピー性皮膚炎の有病率の増加、新規薬剤や治療オプションに対する需要の増加、認知度の向上、より良い治療に対する患者の要望の高まり、治療オプションの進歩といった要因によって牽引されています。

市場力学

新規薬剤と治療オプションに対する需要の増加がアトピー性皮膚炎市場の成長を牽引

アトピー性皮膚炎市場は、新規薬剤や治療オプションに対する需要の高まりにより、大きな成長を遂げています。患者やヘルスケアプロバイダーは、アトピー性皮膚炎患者の症状コントロールや長期管理、QOLの向上につながる革新的な治療法を求めています。

市場成長の主な促進要因の一つは、アトピー性皮膚炎に関与する免疫経路を特異的に標的とする生物学的製剤の開拓です。モノクローナル抗体などの生物学的製剤は、アトピー性皮膚炎に伴う炎症やかゆみを効果的に抑えることで、臨床試験において有望な結果を示しています。これらの薬剤は、従来の全身療法に比べて全身的な副作用が少なく、的を絞ったアプローチを提供します。その結果、生物学的製剤の需要は増加傾向にあり、製薬会社による研究開発への投資の増加につながっています。

例えば、ファイザー社は2023年2月、米国食品医薬品局（FDA）がCIBINQO（R）（一般名：アブロシチニブ）の追加新薬承認申請（sNDA）を行い、生物学的製剤を含む他の全身性製剤で十分なコントロールが得られない、またはそれらの使用が望ましくない難治性の中等度から重度のアトピー性皮膚炎（AD）の青少年（12歳から18歳未満）に適応を拡大したと発表しました。CIBINQOはこれまで、18歳以上の成人のみを適応症として承認されていました。

さらに、有効性と安全性が改善された外用剤に対する需要が高まっています。患者は、従来のコルチコステロイドクリームに代わる、便利で使いやすく、非ステロイド性のものを求めています。このような需要に応えるため、製薬会社はカルシニューリン阻害剤やホスホジエステラーゼ-4阻害剤など、アトピー性皮膚炎の症状に的を絞った、より長期的な管理を可能にする先進的な外用剤の開発を進めています。

アトピー性皮膚炎に対する意識の高まりも市場の成長を促進

患者支援団体、皮膚科協会、ヘルスケア団体は、アトピー性皮膚炎に関する認知度向上に積極的に取り組んでいます。これらの団体は、教育リソースやサポートネットワークを提供し、患者とその家族をエンパワーするためのイニシアチブを推進しています。患者がアトピー性皮膚炎についての知識を深めることで、適切な治療を受け、利用可能な治療法を検討する可能性が高まる。

近年、アトピー性皮膚炎についてヘルスケアプロバイダーを教育する取り組みが増加しています。継続的な医学教育プログラム、学会、研究発表は、皮膚科医、プライマリケア医、その他のヘルスケア専門家におけるアトピー性皮膚炎の知識と理解の向上に焦点を当てています。医療従事者の意識の向上は、より良い診断、必要な場合の専門医への紹介、適切な治療の推奨につながります。

例えば、2023年3月、皮膚疾患治療のための革新的な製品の開発、商業化、マーケティングを専門とする医療技術企業であるSTRATA Skin Sciences, Inc.は、新しいXTRACウェブサイト（www.xtracclear.com）の開設を発表しました。この新しいウェブサイトでは、乾癬、白斑、アトピー性皮膚炎（湿疹）治療のためのXTRACエキシマレーザー治療について患者を啓蒙しています。

治療費の高さが市場成長の妨げになります

アトピー性皮膚炎は慢性疾患であり、症状を効果的に管理するには長期間の治療が必要となります。この治療期間の長期化は、患者にとって多額の累積費用をもたらす可能性があります。処方薬、頻繁な受診、臨床検査、支持療法に関連する費用は、長期間に渡って積み重なり、個人やヘルスケアシステムにとって経済的な課題となります。

アトピー性皮膚炎の治療に対する保険適用範囲は様々で、保険プランによっては、特定の薬や治療の費用を完全にカバーできない場合もあります。高額な免責金額、自己負担額、事前承認の必要性などが、高額な治療を受ける際の障壁となります。このような保険が適用されなかったり、償還が制限されたりすることで、患者が適切な治療を求めたり、効果が低い可能性があり、費用も抑えられる別の治療法を選択したりすることを妨げる可能性があります。

COVID-19の影響分析

COVID-19の流行はアトピー性皮膚炎市場に大きな影響を与えました。アトピー性皮膚炎に関連する多くの臨床試験や研究活動は、パンデミックのために延期または保留されました。ヘルスケア資源と調査努力の焦点はCOVID-19への対応に移り、COVIDに関連しない疾患から注意と資源が逸れました。このような臨床試験や研究の遅れは、将来のアトピー性皮膚炎の新しい治療法の開発や利用可能性に影響を与える可能性があります。

ロシア・ウクライナ紛争影響分析

ロシア・ウクライナ紛争は世界のアトピー性皮膚炎市場に中程度の影響を与えると推定されます。紛争は医薬品や医療機器のサプライチェーンを混乱させる可能性があり、影響を受けた地域におけるアトピー性皮膚炎治療薬の入手に影響を与える可能性があります。製造施設や輸送ルートが寸断されれば、医薬品の生産、流通、入手に遅れが生じ、患者が必要な治療を受けられるかどうかに影響する可能性があります。

目次

第1章 調査手法と調査範囲

第2章 定義と概要

第3章 エグゼクティブサマリー

第4章 市場力学

  • 影響要因
    • 促進要因
      • 新規薬剤および治療オプションに対する需要の増加
      • アトピー性皮膚炎に対する意識の高まり
    • 抑制要因
      • アトピー性皮膚炎治療に伴う副作用
    • 機会
      • 治療オプションにおける継続的な技術進歩
    • 影響分析

第5章 産業分析

  • ポーターの5フォース分析
  • サプライチェーン分析
  • 価格分析
  • 規制分析

第6章 COVID-19分析

第7章 重症度別

  • 軽度
  • 中等度
  • 重度

第8章 治療タイプ別

  • 副腎皮質ステロイド
  • 抗ヒスタミン薬
  • カルシニューリン阻害薬
  • 免疫調節薬
  • 生物製剤
  • PDE-4阻害薬
  • その他

第9章 流通チャネル別

  • 病院薬局
  • 小売薬局
  • オンライン薬局

第10章 地域別

  • 北米
    • 米国
    • カナダ
    • メキシコ
  • 欧州
    • ドイツ
    • 英国
    • フランス
    • スペイン
    • イタリア
    • その他欧州
  • 南米
    • ブラジル
    • アルゼンチン
    • その他南米
  • アジア太平洋
    • 中国
    • インド
    • 日本
    • オーストラリア
    • その他アジア太平洋地域
  • 中東・アフリカ

第11章 競合情勢

  • 競合シナリオ
  • 市況/シェア分析
  • M&A分析

第12章 企業プロファイル

  • Pfizer Inc.
    • 会社概要
    • 製品ポートフォリオと説明
    • 財務概要
    • 主な発展
  • Regeneron Pharmaceuticals Inc.
  • Novartis AG
  • Sanofi S.A.
  • AbbVie Inc.
  • Eli Lilly and Company
  • Galderma Inc.
  • Mylan N.V.
  • LEO Pharma Inc.
  • Valeant Pharmaceuticals

第13章 付録

目次
Product Code: PH79

Market Overview

The global atopic dermatitis market reached US$ 5.8 billion in 2022 and is projected to witness lucrative growth by reaching up to US$ 16.5 billion by 2030. The global atopic dermatitis market is expected to exhibit a CAGR of 14.4% during the forecast period (2023-2030). The increasing research and development activities to explore new therapeutic approaches and identify innovative drugs for atopic dermatitis driving up demand for atopic dermatitis market trends.

The atopic dermatitis market is experiencing significant growth worldwide. The global atopic dermatitis market is witnessing a rise in the development of innovative therapies, including biologic agents, targeted topical treatments, and personalized medicine approaches. Biologics, such as monoclonal antibodies, have shown better results in clinical trials by targeting specific immune pathways involved in atopic dermatitis. Additionally, advancements in drug delivery systems and the introduction of novel topical formulations aim to improve convenience, efficacy, and patient compliance.

The atopic dermatitis market is driven by the factors such as the increasing prevalence of atopic dermatitis, increasing demand for novel drugs and treatment options, increasing awareness, growing patient demand for better treatment, and advancements in treatment options.

Market Dynamics

Increasing Demand for Novel Drugs and Treatment Options Drive the Growth of the Atopic Dermatitis Market

The atopic dermatitis market is experiencing significant growth due to the increasing demand for novel drugs and treatment options. Patients and healthcare providers are seeking innovative therapies that can provide better symptom control, long-term management, and improved quality of life for individuals with atopic dermatitis.

One of the primary drivers of market growth is the development of biologic drugs specifically targeting the immune pathways involved in atopic dermatitis. Biologics, such as monoclonal antibodies, have shown promising results in clinical trials by effectively reducing inflammation and itching associated with the condition. These drugs offer a targeted approach with fewer systemic side effects compared to traditional systemic therapies. As a result, the demand for biologics is on the rise, leading to increased investments in research and development by pharmaceutical companies.

For instance, in February 2023, Pfizer Inc. announced that the United States (U.S.) Food and Drug Administration (FDA) approved its supplemental New Drug Application (sNDA) for CIBINQO® (abrocitinib), expanding its indication to include adolescents (12 to <18 years) with refractory, moderate-to-severe atopic dermatitis (AD) whose disease is not adequately controlled with other systemic drug products, including biologics, or when the use of those therapies is inadvisable. CIBINQO was previously approved only for the treatment of adults 18 years and older.

Additionally, there is a growing demand for topical formulations with improved efficacy and safety profiles. Patients are looking for convenient, easy-to-use, and non-steroidal alternatives to traditional corticosteroid creams. In response to this demand, pharmaceutical companies are developing advanced topical treatments, including calcineurin and phosphodiesterase-4 inhibitors, which offer targeted action and better long-term management of atopic dermatitis symptoms.

Rising Awareness About Atopic Dermatitis Also Drives the Growth of the Market

Patient advocacy groups, dermatology associations, and healthcare organizations have been actively involved in raising awareness about atopic dermatitis. These groups provide educational resources, and support networks, and promote initiatives to empower patients and their families. Patients becoming more informed about atopic dermatitis makes them more likely to seek appropriate medical attention and explore available treatment options.

Efforts to educate healthcare providers about atopic dermatitis have increased in recent years. Continuing medical education programs, conferences, and research publications have focused on improving the knowledge and understanding of atopic dermatitis among dermatologists, primary care physicians, and other healthcare professionals. Enhanced awareness among healthcare providers leads to better diagnosis, referral to specialists when needed, and appropriate treatment recommendations.

For instance, in March 2023, STRATA Skin Sciences, Inc., a medical technology company dedicated to developing, commercializing, and marketing innovative products for the treatment of dermatologic conditions, announced the launch of the new XTRAC website, www.xtracclear.com. The new website educates patients on XTRAC excimer laser therapy for the treatment of psoriasis, vitiligo, and atopic dermatitis (eczema).

The High Cost of the Treatment will Hamper the Growth of the Market.

Atopic dermatitis is a chronic condition that may require long-term treatment to manage symptoms effectively. This prolonged duration of treatment can result in significant cumulative costs for patients. Expenses associated with prescription medications, frequent doctor visits, laboratory tests, and supportive care can add up over time, posing financial challenges for individuals and healthcare systems.

Insurance coverage for atopic dermatitis treatments may vary, and some insurance plans may not fully cover the costs of certain medications or therapies. High deductibles, co-pays, and prior authorization requirements can create barriers to accessing expensive treatments. This lack of coverage or limited reimbursement can deter patients from seeking appropriate care or opting for alternative, potentially less effective, and less costly treatment options.

COVID-19 Impact Analysis

The COVID-19 pandemic significantly impacted the atopic dermatitis market. Many clinical trials and research activities related to atopic dermatitis have been delayed or put on hold due to the pandemic. The focus of healthcare resources and research efforts has shifted towards addressing COVID-19, diverting attention and resources away from non-COVID-related conditions. This delay in clinical trials and research can impact the development and availability of new treatments for atopic dermatitis in the future.

Russia-Ukraine War Impact Analysis

The Russia-Ukraine conflict is estimated to moderately impact the global atopic dermatitis market. The conflict can disrupt the supply chains of pharmaceutical products and medical devices, which could affect the availability of atopic dermatitis treatments in affected regions. If manufacturing facilities or transportation routes are disrupted, it may lead to delays in the production, distribution, and availability of medications, affecting patients' access to necessary treatments.

Segment Analysis

The global atopic dermatitis market is segmented based on disease severity, treatment type, distribution channel, and region.

Corticosteroids from the Treatment Type Segment Accounts for 25.6% of the Atopic Dermatitis Market Share

Corticosteroids are widely used in the treatment of atopic dermatitis due to their anti-inflammatory properties, which help to reduce itching, redness, and inflammation associated with the condition. They are available in various formulations, including creams, ointments, lotions, and foams, allowing for topical application to affected areas.

Corticosteroids are considered the mainstay of treatment for atopic dermatitis and are often prescribed as a first-line therapy for mild to moderate cases. They provide rapid relief of symptoms and have a well-established efficacy profile. Their widespread use and effectiveness contribute to their dominant market position.

For instance, in April 2022, At 16 weeks, 70 percent of patients with moderate-to-severe atopic dermatitis (AD) receiving lebrikizumab combined with standard-of-care topical corticosteroids (TCS) achieved at least 75 percent improvement in overall disease severity (EASI-75*) in the ADhere trial, Eli Lilly and Company announced at the 4th Annual Revolutionizing Atopic Dermatitis (RAD) Conference. Lebrikizumab, an investigational IL-13 inhibitor, also showed improvements in itch, sleep interference, and quality of life when combined with TCS, compared to placebo plus TCS.

Geographical Analysis

North America Accounted for Approximately 39.9% of the Market Share in 2022, Owing to the Advanced Healthcare Infrastructure and Technological Advancements

North America boasts well-developed healthcare systems with a strong emphasis on dermatology and skin health. The region has a robust network of healthcare facilities, including specialized dermatology clinics, research institutions, and academic centers. This advanced infrastructure enables efficient diagnosis, treatment, and management of atopic dermatitis, attracting patients seeking high-quality care.

North America is at the forefront of technological advancements in healthcare, including in the field of dermatology. Innovative diagnostic tools, imaging techniques, and therapeutic modalities have been widely adopted in the region. Technological advancements, such as telemedicine, electronic health records, and digital health platforms, have facilitated remote consultations, access to medical information, and enhanced patient care management for individuals with atopic dermatitis.

Competitive Landscape

The major global players in the atopic dermatitis market include: Pfizer Inc., Allergan Plc., Novartis AG, Sanofi S.A., AbbVie Inc., Eli Lilly and Company, Galderma Inc., Mylan N.V., LEO Pharma Inc., Regeneron Pharmaceuticals Inc., and Valeant Pharmaceuticals.

Why Purchase the Report?

  • To visualize the global atopic dermatitis market segmentation based on disease severity, treatment type, distribution channel, and region, as well as understand key commercial assets and players.
  • Identify commercial opportunities by analyzing trends and co-development.
  • Excel data sheet with numerous data points of atopic dermatitis market-level with all segments.
  • PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
  • Product mapping available as Excel consisting of key products of all the major players.

The global atopic dermatitis market report would provide approximately 53 tables, 54 figures, and 195 Pages.

Target Audience 2023

  • Manufacturers/ Buyers
  • Industry Investors/Investment Bankers
  • Research Professionals
  • Emerging Companies

Table of Contents

1. Methodology and Scope

  • 1.1. Research Methodology
  • 1.2. Research Objective and Scope of the Report

2. Definition and Overview

3. Executive Summary

  • 3.1. Snippet by Disease Severity
  • 3.2. Snippet by Treatment Type
  • 3.3. Snippet by End User
  • 3.4. Snippet by Region

4. Dynamics

  • 4.1. Impacting Factors
    • 4.1.1. Drivers
      • 4.1.1.1. Increasing Demand for Novel Drugs and Treatment Options
      • 4.1.1.2. Rising Awareness About Atopic Dermatitis
    • 4.1.2. Restraints
      • 4.1.2.1. Side Effects Associated with Atopic Dermatitis Treatment
    • 4.1.3. Opportunity
      • 4.1.3.1. Continuous Technological Advancements in Treatment Options
    • 4.1.4. Impact Analysis

5. Industry Analysis

  • 5.1. Porter's 5 Force Analysis
  • 5.2. Supply Chain Analysis
  • 5.3. Pricing Analysis
  • 5.4. Regulatory Analysis

6. COVID-19 Analysis

  • 6.1. Analysis of COVID-19
    • 6.1.1. Scenario Before COVID-19
    • 6.1.2. Scenario During COVID-19
    • 6.1.3. Scenario Post COVID-19
  • 6.2. Pricing Dynamics Amid COVID-19
  • 6.3. Demand-Supply Spectrum
  • 6.4. Government Initiatives Related to the Market During the Pandemic
  • 6.5. Manufacturer's Strategic Initiatives
  • 6.6. Conclusion

7. By Disease Severity

  • 7.1. Introduction
    • 7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Disease Severity
    • 7.1.2. Market Attractiveness Index, By Disease Severity
  • 7.2. Mild *
    • 7.2.1. Introduction
    • 7.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 7.3. Moderate
  • 7.4. Severe

8. By Treatment Type

  • 8.1. Introduction
    • 8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment Type
    • 8.1.2. Market Attractiveness Index, By Treatment Type
  • 8.2. Corticosteroids *
    • 8.2.1. Introduction
    • 8.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 8.3. Antihistamines
  • 8.4. Calcineurin Inhibitors
  • 8.5. Immunomodulators
  • 8.6. Biologics
  • 8.7. PDE-4 Inhibitors
  • 8.8. Others

9. By Distribution Channel

  • 9.1. Introduction
    • 9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
    • 9.1.2. Market Attractiveness Index, By Distribution Channel
  • 9.2. Hospital Pharmacies *
    • 9.2.1. Introduction
    • 9.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 9.3. Retail Pharmacies
  • 9.4. Online Pharmacies

10. By Region

  • 10.1. Introduction
    • 10.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
    • 10.1.2. Market Attractiveness Index, By Region
  • 10.2. North America
    • 10.2.1. Introduction
    • 10.2.2. Key Region-Specific Dynamics
    • 10.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Disease Severity
    • 10.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment Type
    • 10.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
    • 10.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 10.2.6.1. U.S.
      • 10.2.6.2. Canada
      • 10.2.6.3. Mexico
  • 10.3. Europe
    • 10.3.1. Introduction
    • 10.3.2. Key Region-Specific Dynamics
    • 10.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Disease Severity
    • 10.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment Type
    • 10.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
    • 10.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 10.3.6.1. Germany
      • 10.3.6.2. U.K.
      • 10.3.6.3. France
      • 10.3.6.4. Spain
      • 10.3.6.5. Italy
      • 10.3.6.6. Rest of Europe
  • 10.4. South America
    • 10.4.1. Introduction
    • 10.4.2. Key Region-Specific Dynamics
    • 10.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Disease Severity
    • 10.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment Type
    • 10.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
    • 10.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 10.4.6.1. Brazil
      • 10.4.6.2. Argentina
      • 10.4.6.3. Rest of South America
  • 10.5. Asia-Pacific
    • 10.5.1. Introduction
    • 10.5.2. Key Region-Specific Dynamics
    • 10.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Disease Severity
    • 10.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment Type
    • 10.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
    • 10.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 10.5.6.1. China
      • 10.5.6.2. India
      • 10.5.6.3. Japan
      • 10.5.6.4. Australia
      • 10.5.6.5. Rest of Asia-Pacific
  • 10.6. Middle East and Africa
    • 10.6.1. Introduction
    • 10.6.2. Key Region-Specific Dynamics
    • 10.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Disease Severity
    • 10.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment Type
    • 10.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel

11. Competitive Landscape

  • 11.1. Competitive Scenario
  • 11.2. Market Positioning/Share Analysis
  • 11.3. Mergers and Acquisitions Analysis

12. Company Profiles

  • 12.1. Pfizer Inc. *
    • 12.1.1. Company Overview
    • 12.1.2. Product Portfolio and Description
    • 12.1.3. Financial Overview
    • 12.1.4. Key Developments
  • 12.2. Regeneron Pharmaceuticals Inc.
  • 12.3. Novartis AG
  • 12.4. Sanofi S.A.
  • 12.5. AbbVie Inc.
  • 12.6. Eli Lilly and Company
  • 12.7. Galderma Inc.
  • 12.8. Mylan N.V.
  • 12.9. LEO Pharma Inc.
  • 12.10. Valeant Pharmaceuticals

LIST NOT EXHAUSTIVE

13. Appendix

  • 13.1. About Us and Services
  • 13.2. Contact Us